Skip to content

MondayNightIBD | IBD Trials to Watch: Part 2 ~ IL-23s & ACT
Sep 15, 2025 | Bruce Sands, MD, MS
**Pre-assessment**

Before you participate in this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.Where are you in your career? (Required.)
2.#NewIBDdrugOntheBlock
What’s next in the IL23 story?

#ANTHEM-UC is a phase 2b trial that assessed #Icotrokinra efficacy vs placebo in mod-severe UC

What is the MOA of this drug
🔑mAb = monoclonal antibody
🔑i = inhibitor(Required.)
3.#NewIBDdrugsOntheBlock

🔮 Is Dual Targeted Therapy (DTT) in our near future to optimize treatment response in #IBD ?

🔮Which DTT trials are in the works/ happening ?(Required.)
Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

🔗 Proceed to post-survey (post-survey completion must occur on or after activity launch date to be valid for claiming credit)
Privacy & Cookie Notice